BACKGROUND AND AIMS: 15-Hydroxprostaglandin dehydrogenase (15-PGDH) mediates a colon neoplasia suppressor pathway, acting through metabolic antagonism of cyclooxygenase-mediated colon carcinogenesis. To determine whether the colon tumor prevention activity of 15-PGDH acts as a constant or variable effect among individuals, we determined whether 15-PGDH levels remain stable over subsite and time in the human colon, determined the extent of differences in 15-PGDH levels between different individuals, and determined whether 15-PGDH modulation mediates any part of the anti-colon tumor effect of aspirin. METHODS: Using real-time PCR, we measured 15-PGDH mRNA to determine the correlation of 15-PGDH level in replicate colon biopsies, in biopsies from throughout the length of the colon, in repeat biopsies taken 4 months apart, and in paired biopsies of individuals taken before and after aspirin treatment, and by Western-blot for 15-PGDH protein in mice. RESULTS: Colonic 15-PGDH levels varied 4.4-fold across the human population. Within individuals, 15-PGDH levels proved highly reproducible (r=0.81 in duplicate biopsies) and stable along the length of the colon, with average 15-PGDH levels deviating by only 17% from rectum to cecum. An individual's 15-PGDH levels are also highly stable over time, with a median coefficient of variation over a 4-month interval of only 12%. Last, colonic 15-PGDH levels proved resistant to alteration by aspirin, with only a 10% difference in 15-PGDH levels measured before and after aspirin treatment. CONCLUSIONS: 15-PGDH levels vary across the population in a stable and reproducible manner, and are resistant to alteration by aspirin. 15-PGDH represents an independent target for modulation by candidate colon tumor chemopreventive agents.
BACKGROUND AND AIMS: 15-Hydroxprostaglandin dehydrogenase (15-PGDH) mediates a colon neoplasia suppressor pathway, acting through metabolic antagonism of cyclooxygenase-mediated colon carcinogenesis. To determine whether the colon tumor prevention activity of 15-PGDH acts as a constant or variable effect among individuals, we determined whether 15-PGDH levels remain stable over subsite and time in the human colon, determined the extent of differences in 15-PGDH levels between different individuals, and determined whether 15-PGDH modulation mediates any part of the anti-colon tumor effect of aspirin. METHODS: Using real-time PCR, we measured 15-PGDH mRNA to determine the correlation of 15-PGDH level in replicate colon biopsies, in biopsies from throughout the length of the colon, in repeat biopsies taken 4 months apart, and in paired biopsies of individuals taken before and after aspirin treatment, and by Western-blot for 15-PGDH protein in mice. RESULTS:Colonic 15-PGDH levels varied 4.4-fold across the human population. Within individuals, 15-PGDH levels proved highly reproducible (r=0.81 in duplicate biopsies) and stable along the length of the colon, with average 15-PGDH levels deviating by only 17% from rectum to cecum. An individual's 15-PGDH levels are also highly stable over time, with a median coefficient of variation over a 4-month interval of only 12%. Last, colonic 15-PGDH levels proved resistant to alteration by aspirin, with only a 10% difference in 15-PGDH levels measured before and after aspirin treatment. CONCLUSIONS:15-PGDH levels vary across the population in a stable and reproducible manner, and are resistant to alteration by aspirin. 15-PGDH represents an independent target for modulation by candidate colon tumor chemopreventive agents.
Authors: Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Andrew T Chan; Nadir Arber; John Burn; Whay Kuang Chia; Peter Elwood; Mark A Hull; Richard F Logan; Peter M Rothwell; Karsten Schrör; John A Baron Journal: Cancer Prev Res (Phila) Date: 2011-11-14
Authors: Carol W M Chan; Newton A Wong; Ying Liu; David Bicknell; Helen Turley; Laura Hollins; Crispin J Miller; Jennifer L Wilding; Walter F Bodmer Journal: Proc Natl Acad Sci U S A Date: 2009-02-02 Impact factor: 11.205
Authors: Min Yan; Seung-Jae Myung; Stephen P Fink; Earl Lawrence; James Lutterbaugh; Peiying Yang; Xiaohua Zhou; Danielle Liu; Ronald M Rerko; Joseph Willis; Dawn Dawson; Hsin-Hsiung Tai; Jill S Barnholtz-Sloan; Robert A Newman; Monica M Bertagnolli; Sanford D Markowitz Journal: Proc Natl Acad Sci U S A Date: 2009-05-22 Impact factor: 11.205
Authors: John Burn; Anne-Marie Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop Journal: Lancet Date: 2011-10-27 Impact factor: 79.321
Authors: E Bastiaannet; K Sampieri; O M Dekkers; A J M de Craen; M P P van Herk-Sukel; V Lemmens; C B M van den Broek; J W Coebergh; R M C Herings; C J H van de Velde; R Fodde; G J Liefers Journal: Br J Cancer Date: 2012-03-27 Impact factor: 7.640
Authors: Stephen P Fink; Mai Yamauchi; Reiko Nishihara; Seungyoun Jung; Aya Kuchiba; Kana Wu; Eunyoung Cho; Edward Giovannucci; Charles S Fuchs; Shuji Ogino; Sanford D Markowitz; Andrew T Chan Journal: Sci Transl Med Date: 2014-04-23 Impact factor: 17.956
Authors: Stephen P Fink; Dawn M Dawson; Yongyou Zhang; Adam Kresak; Earl G Lawrence; Peiying Yang; Yanwen Chen; Jill S Barnholtz-Sloan; Joseph E Willis; Levy Kopelovich; Sanford D Markowitz Journal: Carcinogenesis Date: 2014-12-10 Impact factor: 4.944
Authors: Jiping Wang; Nancy L Cho; Sanford D Markowitz; Monica M Bertagnolli; Ann G Zauber; Meier Hsu; Dawn Dawson; Amitabh Srivastava; Kisha A Mitchell-Richards Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-16 Impact factor: 4.254
Authors: Sushma S Thomas; Karen W Makar; Lin Li; Yingye Zheng; Peiying Yang; Lisa Levy; Rebecca Yvonne Rudolph; Paul D Lampe; Min Yan; Sanford D Markowitz; Jeannette Bigler; Johanna W Lampe; John D Potter Journal: BMC Med Genet Date: 2015-03-24 Impact factor: 2.103
Authors: David A Drew; Samantha M Chin; Katherine K Gilpin; Melanie Parziale; Emily Pond; Madeline M Schuck; Kathleen Stewart; Meaghan Flagg; Crystal A Rawlings; Vadim Backman; Peter J Carolan; Daniel C Chung; Francis P Colizzo; Matthew Freedman; Manish Gala; John J Garber; Curtis Huttenhower; Dmitriy Kedrin; Hamed Khalili; Douglas S Kwon; Sanford D Markowitz; Ginger L Milne; Norman S Nishioka; James M Richter; Hemant K Roy; Kyle Staller; Molin Wang; Andrew T Chan Journal: Trials Date: 2017-02-01 Impact factor: 2.279
Authors: ElKhansa Sidahmed; Ananda Sen; Jianwei Ren; Arsh Patel; D Kim Turgeon; Mack T Ruffin; Dean E Brenner; Zora Djuric Journal: Nutr Cancer Date: 2016-08-22 Impact factor: 2.900